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ABSTRACT
Background: Visceral leishmaniasis (VL) (Kala-Azar) is one of the most important health-related parasitic infec-
tious diseases. VL is an endemic disease in Iran and more than 80 countries worldwide. The aim of this study 
was to investigate the Epidemiological and Clinical Characteristics of Infants with VL.
Methodology: This cross-sectional study was conducted on 31 patients with diagnosis of VL in Ardabil city 
hospital, Iran, during 2011–2016. The questionnaire included demographic information, such as age, gender, 
weight, place of living, level of family education, family history of diseases, and symptoms, to complete the 
specified goals.
Results: Of all the cases, 18 (58.1%) were girls and the rest were boys. The average age of the patients was 
25.8 ± 32.3 months. More than half (61.3%) of the patients were in the Moghan County (Ghermi, Parsabad, 
Aslandooz). Clinical symptoms began in 10 (32.3%) patients in winter. Fever was the most commonly observed 
clinical symptom in children with VL (93.5%). Of 27 children with a history of symptom onset, 17 children (63%) 
were diagnosed at the interval of 2–4 weeks. The result of the direct agglutination test (DAT) was positive in 
27 children (87.1%) and the rest were negative. In the clinical presentation of patients, fever, anemia, and 
enlargement of the spleen and liver were common.
Conclusion: The use of DAT in combination with clinical symptoms seems to be more suitable for initiating 
treatment than bone marrow aspiration in all the patients.
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Introduction
Visceral leishmaniasis (VL), also known as kala-azar 
black fever, is one of the infectious-parasitic diseases 
that threatens life and in term of health is very important. 
Attention to VL as a public health problem has been 
increased. Based on large diversity of clinical forms and 
epidemiological situations of the disease, it represents that 
each focal point needs specific principles and procedures 
for control. VL is an endemic disease in Iran and more 
than 80 countries worldwide. According to the World 
Health Organization, 500,000 new cases are annually 
reported and of them, at least 50,000 are deaths that have 
occurred in the world. More than 90% of VL cases occur 
in the Indian subcontinent (India, Bangladesh, Nepal), 
Sudan, Ethiopia and Brazil [1–3].
Kala-azar in the rural areas is more common than urban 
areas. Kala-azar in Iran is of Mediterranean type that 
occurs more in infants and children under 12 years. 
In children under 5 years with immunodeficiency, the 
primary factor is Leishmania infantum, while in secondary 
the causing agent is Leishmania tropica, which especially 
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affects immunodeficient individuals. The conveyer of the 
disease is a special species of phlebotomizing and the 
parasite tank is dogs. The disease is mostly sporadic in the 
different regions but in some areas of Iran, especially in 
the northwest and southwest, including the provinces of 
Ardabil, East Azerbaijan, Fars, and Bushehr where it has 
been reported as endemic form and 100–300 new cases 
are reported annually [4–6]. From 1993 to 2012, about 
2,000 cases of Kala-azar were reported in 31 provinces 
of Iran and 44.6% of them were in the north-west region. 
The average number of diagnosed cases in Iran was 0.449 
per 100,000 and the highest prevalence of disease was in 
Ardabil with estimation of 57 cases per 100,000 [7–10].
The disease usually occurs without any specific 
symptoms and it progresses slowly. Its multiple clinical 
symptoms are an irregular and raging fever to 40°C 
with restlessness, spleen pain, cough and weight loss, 
enlargement of the spleen and liver; resulting in enlarged 
abdominal area, anemia, decrease in the number of 
blood cells (red blood cells (RBC), white blood cells 
(WBCs), and platelets), and swelling of the face, arms, 
and legs [9–11]. The illness of kala-azar because of a 
change in the color of the patient’s skin and due to its 
high mortality, it is known as the black disease. The 
cause of death is usually caused by secondary infections 
and internal bleeding. Individuals with antibody titers 
against leishmaniasis greater than 1:3,200 is considered 
as a positive serology [direct agglutination test (DAT) 
Positive], approximately 75% patients have clinical 
symptoms and positive physical examination. The most 
common symptom in the first stage is pale appearance 
and a long fever, whereas in other stages the symptoms 
are splenomegaly, hepatomegaly, and lymphadenopathy 
[10–12]. Kala-azar is an infectious and systemic disease 
which if not treated, results in mortality and its early 
diagnosis is the key. On the other hand, Kala-azar is a 
complex disease because its clinical signs are similar to 
other common diseases, such as Malaria and typhoid, 
sometimes these diseases are seen with kala-azar. The 
most definite method for diagnosis is the observation 
of amastigotes in biopsy or samples of bone marrow 
but given the fact that the method is invasive and its 
sensitivity and specificity are not superior to serology, 
it seems the serology method (DAT) is good alternative 
[13–15]. The importance of this disease is due to the death 
of 100% of untreated patients and significant mortality 
in patients with immunosuppressive disorder and most 
childhood infections. In a study on the patients with kala-
azar who were hospitalized in northwest of Iran, only 
2.8% had mortality which was due to the delayed referral 
of patients to treatment center followed by secondary 
infections and constipation [14–16].
Climate and other environmental changes are potential 
factors for expanding the geographical range of carriers 
and the transfer of leishmaniasis in the future. Various 
weather and humidity conditions affect serology that is 
due to mosquito activity in the climate. It seems that the 
number of infected dogs in each region is the biggest 
risk factor in the transfer of kala-azar [15–18]. Due to 
the importance of early and timely diagnosis of kala-
azar and consequently, the treatment of it due to severe 
fecundity as well as climatic and environmental changes 
in different areas, and its effect on the spread of disease, 
the changes in the epidemiological pattern and clinical 
features of the disease were examined in the study.
Subjects and Methods
This descriptive cross-sectional study has been done 
on 31 patients with diagnosis of kala-azar, who were 
hospitalized in Ardabil city hospital, Iran, during 
2011–2016. A questionnaire containing demographic 
information, such as age, gender, height, weight, 
residence place, family education, family history, and 
disease’s symptoms, was completed for the patients 
and the collected data was analyzed by descriptive and 
analytical statistical methods in SPSS version 21.
Results
Of all children, 18 (58.1%) were girls and the rest 
were boys, 25 (80.6%) were under the age of 2 years, 
of which, 14 (56%) were girls and 11 (44%) boys. 
The average age of patients was 25.8 ± 32.3 months. 
Most of the patients (67.7%) lived in the Moghan 
area (Ghermi, Parsabad, Bilesavar) (Table 1). Of all 
children, 21 (67.7%) were in the rural and the rest 
were in urban. Clinical symptoms began in 10 (32.3%) 
patients in winter. The onset of clinical symptoms 
was in October and February, each with 5% (16.1%) 
which was more than other months (Figure 1). Fever 
was the most common observed clinical symptom 
in children with kala-azar (93.5%) (Figure 2). Of all 
children, 17 (63%) were diagnosed between 2 and 4 
weeks of onset of clinical signs of VL. Among children 
with specific laboratory findings; 26 children (83.9%) 
had anemia, 16 (51.6%) leukopenia, and 15 (48.6%) 
thrombocytopenia (Table 2). The result of the DAT test 
was positive in 27 children (87.1%) and was negative 
in the rest. Out of 24 cases of bone marrow aspiration 
(BMA), in 14 cases (45.2%) there was evidence for 
confirmation of VL. False negative values in the BMA 
was 32.3% and in DAT was 12.9% (Table 3). In all 31 
patients with kala-azar in this study, Glucantime was 
the first line drug for all the cases. Of these patients, 23 
Table 1. Frequency of patients by city and sex.
City
Girl Boy
n % n %
Ardabil 4 22.2 2 15.4
Meshkin shahr 1 5.55 1 7.7
Moghan area 11 61.1 10 76.9
Astara 1 5.55 0 0
Khalkhal 1 5.55 0 0
Total 18 58.1 13 41.9
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(74.1%) had appropriate response to the treatment and 
8 (25.9%) had inappropriate response; one patient died 
before the beginning of secondary drug and remaining 
cases showed the appropriate response to the secondary 
drug. It should be noted that the secondary drug in 
seven patients that did not respond to Glucantime was 
Amphotericin B. Patients treated with Glucantime 
did not show significant complications. Of the seven 
patients who received amphotericin during their course 
of treatment, 6 (85.7%) developed hypokalemia and 1 
(14.3%) hepatotoxicity.
Discussion
In the present study, 58.1% of the patients with VL were 
girls and the sex ratio was 1.4:1. In a study done by 
Molaie et al. [19], in Ardabil province during the years 
1986–2009, the prevalence of VL was higher in males 
than females (1.3–1). Barati et al. [16] did not find any 
significant difference between the two sexes in term of 
anti-leishmaniasis antibodies. In a study by Mohebali 
[20], the prevalence of VL was 58% in males. In the 
present study, 35% of patients were under 1-year old, 
80.6% were under 2-year old, and 87% were under 5 years 
of age. In a study by Molaie et al. [19], 93% of patients 
were less than 5 years of age and 17% were less than 1 
year. It seems that failure to complete the body's immune 
system, the primary immune system, such as thin skin, 
defective production of antibodies, and defects in the 
quality of performance of B cell and T cells, can be the 
cause of high prevalence of Kala-azar in children under 2 
years of age which requires separate examination. In this 
study, 67.7% of patients were from Moghan areas. Also, 
67.7% of patients lived in the rural areas and the rest 
were from the Urban areas. Based on studies by Mccall 
[14] and Mohebali [20], Ardabil province is one of the 
endemic areas in terms of prevalence of VL. In a study 
by Molaie et al. [19], 66.1% of VL cases were children 
of Meshgin-shar city and 31% of them were in Moghan 
area, the climatic change in these is due to increase in 
the population of transporter and mosquitoes in the soil 
or reservoir due to the growth of agricultural projects, 
this requires ecological and environmental studies of 
reservoirs and carriers that necessitates the induction 
of endemic studies for province's health and control in 
Moghan region. In the present study, the most frequent 
time for the onset of clinical signs was winter (32.3%). In 
a study by Molaie et al. [19], the most frequent incidence 
of VL was in the end of winter and beginning of spring 
(67.7%). It seems that altering the endemic region of the 
disease and climate changes are effective for the disease 
occurrence. By investigating the studies by Molaie [19] 
and Mohebali [20], fever, anemia, and size of spleen 
and liver are common signs that were seen in patients 
with VL. In line with previous studies, fever, anemia, 
splenomegaly, and hepatomegaly were the most common 
clinical signs in the present study. Regarding this finding, 
doing a systemic examination and Complete blood count 
(CBC) screening and antibiotic arbitrary use in these 
patients are very effective in early detection. Laboratory 
evaluation of patients in the present study showed that 
decrease in hemoglobin, white blood cell count and 
platelet count were seen in 83.9%, 51.6%, and 50% 
of patients, respectively. N87.1% of the patients with 
VL had a positive DAT (27 cases of 31 patients). Out 
of 24 cases of BMA, 14 cases (58.3%) had confirmed 
information for the diagnosis of disease; in which four 
patients had positive DAT and two patients had positive 
BMA. According to the results, all the patients do not need 
BMA, it is only required in cases with suspected negative 
DAT. Due to the fact that DAT has false negative less 
than aspiration and since BMA is an invasive method and 
may be many of patients do not consent to doing this test 
and on the other hand, according to the early diagnosis of 
disease, it seems that DAT in combination with clinical 
symptoms to be more appropriate than BMA for starting 
treatment. In the present study, it has been emphasized 
that Glucantime is probably safer than amphotericin 
B, in terms of side effects but the secondary drug has 
more efficacy. However, the sample size in this study to 
investigate this claim is not enough and the confirmation 
requires more extensive clinical trials in the future.
Figure 1. Frequency of onset time of clinical symptoms by 
season and month.
Figure 2. Frequency of observed clinical symptoms in  
patients
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Conclusion
Most of the patients with VL were females. Most cases 
of VL occurred in Ardabil province under the age of 2 
years. The incidence of VL in the winter was higher than 
other seasons. VL is endemic disease in Ardabil and its 
prevalence in the Moghan area and the rural areas are 
higher than other areas. In the clinical presentation of 
patients studied in this study, fever, anemia, and the size 
of spleen and liver were common. The false negative 
cases in the DAT test were lesser than BMA, and in a 
significant percentage of patients performing BMA 
was not satisfactory. The use of DAT in combination 
with clinical symptoms was more appropriate to initiate 
treatment than BMA in all the patients. The results 
showed that glucantime was safer than amphotericin B 
for complications but amphotericin B was more effective.
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